Icariside II inhibits Epithelial-Mesenchymal transition in metastatic osteosarcoma by antagonizing the miR-194/215 cluster via PGK1

• Published in: Biochemical pharmacology Vol. 236; p. 116838
• Main Authors: Hu, Jianping, Chen, Jinhu, Zhao, Caili, Yu, Pei, Xu, Wenjun, Yin, Yong, Yang, Lei, Zhang, Zhenzhen, Kong, Lingyi, Zhang, Chao
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01.06.2025
• Subjects: Animals; Bone Neoplasms - drug therapy; Bone Neoplasms - genetics; Bone Neoplasms - metabolism; Bone Neoplasms - pathology; Cell Line, Tumor; Cell Movement - drug effects; Chemokines; EMT; Epithelial-Mesenchymal Transition - drug effects; Epithelial-Mesenchymal Transition - physiology; Flavonoids - pharmacology; Flavonoids - therapeutic use; Humans; Icariside II; Male; Metastatic osteosarcoma; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs - antagonists & inhibitors; MicroRNAs - genetics; MicroRNAs - metabolism; miR-194/215 cluster; Osteosarcoma - drug therapy; Osteosarcoma - genetics; Osteosarcoma - metabolism; Osteosarcoma - pathology; PGK1; Phosphoglycerate Kinase - antagonists & inhibitors; Phosphoglycerate Kinase - genetics; Phosphoglycerate Kinase - metabolism; Xenograft Model Antitumor Assays - methods; Icariside II; CXCL8; CMAP; qRT-PCR; GSEA; DARTS; CXCL1; Slug; EMT; LINCS; CETSA; Metastatic osteosarcoma; PGK1; miR-194/215 cluster; Chemokines
• ISSN: 0006-2952; 1873-2968; 1873-2968
• DOI: 10.1016/j.bcp.2025.116838

[Display omitted] Osteosarcoma, the most prevalent malignant bone tumor in adolescents, is characterized by its aggressiveness and tendency to metastasize. Despite the advancements in treatment that have improved survival rates for localized cases, metastatic osteosarcoma remains challenging to treat due to the limited efficacy of current therapies and the severe side effects of chemotherapy. Epithelial-mesenchymal transition (EMT) is a key factor in osteosarcoma metastasis, and the miR-194/215 cluster, which is upregulated in osteosarcoma, promotes this process. This study sought to investigate natural compounds that could counteract the miR-194/215 cluster’s effects and inhibit osteosarcoma metastasis. By analyzing miRNA databases and clinical data, a signature gene set for the miR-194/215 cluster was established, and the LINCS database was screened to find natural compounds with antagonistic effects. Icariside II, an active component of Epimedium, was identified as a potential inhibitor and was shown to reduce the migration and invasion of osteosarcoma cells in vitro and lung metastasis in vivo. The study utilized various techniques, including Gene Set Enrichment Analysis (GSEA), Drug Affinity Responsive Target Stability (DARTS), Cellular Thermal Shift Assay (CETSA), molecular docking, and enzyme activity assays, to identify phosphoglycerate kinase 1 (PGK1) as the target protein of Icariside II. It was found that Icariside II competitively inhibits PGK1 by binding to its ADP binding pocket, reducing its activity and thus antagonizing the miR-194/215 cluster’s promotion of EMT in metastatic osteosarcoma. The results suggest that Icariside II could be a promising therapeutic agent for metastatic osteosarcoma, providing new targets and strategies for clinical treatment.